Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Arcutis Biotherapeutics (ARQT)
NASDAQ:ARQT
RESEARCH TOOLSreports
Holding ARQT?
Track your performance easily
Earnings Data
Report Date
Mar 04, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
-$0.28Last Year’s EPS
-$0.72Same Quarter Last Year
Strong Buy
Based on 4 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Nov 06, 2024
|% Change Since: 55.18%
|Next Earnings Date:Mar 04, 2025
Earnings Call Sentiment|Positive
The earnings call showcased significant growth in ZORYVE portfolio sales and gross-to-net improvements, indicating a strong financial performance. While there were some challenges, such as delays in Medicare Part D coverage and minor hurricane impacts, the overall outlook remains positive with strong cash management and expansion in Medicaid coverage.Company Guidance
During Arcutis Biotherapeutics' Q3 2024 earnings call, the company reported a robust performance with the ZORYVE portfolio, showing a 452% year-over-year sales increase and a 45% quarter-over-quarter rise, reaching $44.8 million in net product revenue. Prescription demand surged by 25% from the previous quarter, while new prescriptions grew by 23%. The company also highlighted significant gross-to-net improvements, reducing from the high 50s to the low 50s. Arcutis is making strides in expanding its product label, anticipating approvals for scalp and body psoriasis in 2025 and increasing accessibility to government pay patients, potentially reaching an additional 3.3 million patients. The company has secured Medicaid coverage in several states, advancing its reach and validating its pricing strategy. With the ZORYVE portfolio leading the new prescription share in the branded topical space, Arcutis is poised for continued growth, aiming to shift use away from topical steroids.ZORYVE Portfolio Sales Growth
ZORYVE portfolio sales grew 452% year-over-year and 45% quarter-over-quarter, reaching $44.8 million. TRxs for the ZORYVE portfolio grew 25% quarter-over-quarter, with new prescription growth increasing 23%.
Gross-to-Net Improvements
Gross-to-net improvements reached the low 50% range, a meaningful improvement from the high 50s last quarter.
Expansion of ZORYVE Indications
ZORYVE is expanding with expected approval for scalp and body psoriasis in 2025, and expanded indications for pediatric patients in atopic dermatitis and psoriasis.
Medicaid Coverage Expansion
Secured Medicaid coverage in states representing roughly 4 in 10 Americans, including California, Arizona, Michigan, and Indiana.
Strong Cash Position and Debt Management
Cash and marketable securities were $331 million as of September 30. The company repaid $100 million of its debt facility, significantly lowering interest expenses.
---
ARQT Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
ARQT Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 06, 2024 | $9.66 | $10.40 | +7.66% |
| Aug 14, 2024 | $9.58 | $8.50 | -11.27% |
| May 14, 2024 | $8.13 | $9.24 | +13.65% |
| Feb 27, 2024 | $9.69 | $10.63 | +9.70% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Arcutis Biotherapeutics (ARQT) report earnings?
Arcutis Biotherapeutics (ARQT) is schdueled to report earning on Mar 04, 2025, TBA Not Confirmed.
What is Arcutis Biotherapeutics (ARQT) earnings time?
Arcutis Biotherapeutics (ARQT) earnings time is at Mar 04, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is ARQT EPS forecast?
ARQT EPS forecast for the fiscal quarter 2024 (Q4) is -$0.28.
---